Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of authorized generic TRILIPIX® (fenofibric acid) delayed release capsules, 45 mg and 135 mg, through Global Pharmaceuticals, Impax’s generics division. Under the terms of a settlement agreement, Abbott Laboratories (now AbbVie Inc.) and Fournier Laboratories Ireland Ltd. granted Impax the right to sell an authorized generic as early as July 15, 2013.
Help employers find you! Check out all the jobs and post your resume.
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it is commencing shipment of authorized generic TRILIPIX® (fenofibric acid) delayed release capsules, 45 mg and 135 mg, through Global Pharmaceuticals, Impax’s generics division. Under the terms of a settlement agreement, Abbott Laboratories (now AbbVie Inc.) and Fournier Laboratories Ireland Ltd. granted Impax the right to sell an authorized generic as early as July 15, 2013.
Help employers find you! Check out all the jobs and post your resume.
